Latest Pharma Insights
Wella Appoints CEO, LVMH Names Head of Beauty Group; Appointments Roundup
The Wella Company announces that former Sephora Americas CEO Calvin McDonald will take over as CEO of the hair care marketer April 2. Separately, LVMH names new head of its beauty group and Revlon appoints a chief operations officer.
HBW Insight - February 12, 2026
The Wella Company announces that former Sephora Americas CEO Calvin McDonald will take over as CEO of the hair care marketer April 2. Separately, LVMH names new head of its beauty group and Revlon appoints a chief operations officer.
HBW Insight - February 12, 2026
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story
The Danish firm’s Yorvipath produced strong growth during its first full year on market, and Ascendis expects US approval this year for a weekly competitor to BioMarin’s Voxzogo in achondroplasia.
Scrip - February 12, 2026
The Danish firm’s Yorvipath produced strong growth during its first full year on market, and Ascendis expects US approval this year for a weekly competitor to BioMarin’s Voxzogo in achondroplasia.
Scrip - February 12, 2026
Execs On The Move: February 2–6, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 12, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 12, 2026
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share
The company’s positive topline Phase III results for the oral drug showed improvements in growth and body proportionality, including gains not seen with standard-of-care injections.
Scrip - February 12, 2026
The company’s positive topline Phase III results for the oral drug showed improvements in growth and body proportionality, including gains not seen with standard-of-care injections.
Scrip - February 12, 2026
Paul Hudson’s Legacy At Sanofi: Dupixent And Missed Opportunities
Dupixent grew from a €2bn drug to a €15bn behemoth during Hudson’s six years leading Sanofi, but a decision to end work on a GLP-1 agonist ahead of the metabolic/obesity boom could be a haunting misstep.
Scrip - February 12, 2026
Dupixent grew from a €2bn drug to a €15bn behemoth during Hudson’s six years leading Sanofi, but a decision to end work on a GLP-1 agonist ahead of the metabolic/obesity boom could be a haunting misstep.
Scrip - February 12, 2026
FDA Holds ‘Refresher’ Town Hall On Low-Risk, General Wellness Medical Devices
The US FDA hosted a virtual town hall as a follow-up to final guidance the agency issued last month, which outlines its policy on general wellness medical devices that the agency considers low risk.
Medtech Insight - February 12, 2026
The US FDA hosted a virtual town hall as a follow-up to final guidance the agency issued last month, which outlines its policy on general wellness medical devices that the agency considers low risk.
Medtech Insight - February 12, 2026
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals
After its ProfoundBio and Merus acquisitions in 2024 and 2025, Genmab could add Rina-S and petosemtamab to its two marketed cancer drugs, Epkinly and Tivdak, before its Darzalex royalty stream dries up.
Scrip - February 12, 2026
After its ProfoundBio and Merus acquisitions in 2024 and 2025, Genmab could add Rina-S and petosemtamab to its two marketed cancer drugs, Epkinly and Tivdak, before its Darzalex royalty stream dries up.
Scrip - February 12, 2026
Ipsen Eyes More Deals And Keen On Late-Stage Cancer Assets
CEO David Loew has been speaking about the French group’s external innovation strategy after posting another healthy set of financials.
Scrip - February 12, 2026
CEO David Loew has been speaking about the French group’s external innovation strategy after posting another healthy set of financials.
Scrip - February 12, 2026
Novocure’s Optune Pax First Home-Use Pancreatic Cancer Treatment Device Approved By FDA
Novocure’s Optune Pax is a wearable non-invasive device that uses electrical fields to disrupt the growth of cancer cells. A pivotal trial showed longer survival in patients who used the device than in those treated with chemotherapy alone.
Medtech Insight - February 12, 2026
Novocure’s Optune Pax is a wearable non-invasive device that uses electrical fields to disrupt the growth of cancer cells. A pivotal trial showed longer survival in patients who used the device than in those treated with chemotherapy alone.
Medtech Insight - February 12, 2026
Viking’s Oral Obesity Challenger Moves Fast Into Phase III
The San Diego-based biotech could be among the first rivals to Novo Nordisk and Eli Lilly with VK2735, and an oral version also now moving into a pivotal study.
Scrip - February 12, 2026
The San Diego-based biotech could be among the first rivals to Novo Nordisk and Eli Lilly with VK2735, and an oral version also now moving into a pivotal study.
Scrip - February 12, 2026
Zuellig Bolsters Consumer Health Offering In Asia with Bayer Deal
Singapore's Zuellig Pharma picks up consumer health brands with over 100 years of heritage through deal with Bayer.
HBW Insight - February 12, 2026
Singapore's Zuellig Pharma picks up consumer health brands with over 100 years of heritage through deal with Bayer.
HBW Insight - February 12, 2026
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Generics Bulletin - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Generics Bulletin - February 12, 2026
Samsung Bioepis Secures US Launch Date For Eylea Biosimilar – Though Later Than Others
Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.
Generics Bulletin - February 12, 2026
Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.
Generics Bulletin - February 12, 2026
Five Years To Go: Spotlight On Biosimilar Dupixent
With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.
Generics Bulletin - February 12, 2026
With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.
Generics Bulletin - February 12, 2026
Aspire Picks Up Irish Asset With Caragen Acquisition
UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.
Generics Bulletin - February 12, 2026
UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.
Generics Bulletin - February 12, 2026
Europe Biotech Backers Link Up To Improve Sector’s Health
The European Life Sciences Coalition has been launched to boost investment in the sector.
Scrip - February 12, 2026
The European Life Sciences Coalition has been launched to boost investment in the sector.
Scrip - February 12, 2026
Deals Of The Year 2025 Winners Revealed
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026
Sanofi Replaces CEO Paul Hudson With Merck KGaA’s Belén Garijo
Sanofi’s Paul Hudson will step down and be replaced by Belén Garijo, who will become the French group’s first ever female CEO.
Scrip - February 12, 2026
Sanofi’s Paul Hudson will step down and be replaced by Belén Garijo, who will become the French group’s first ever female CEO.
Scrip - February 12, 2026
Podcast: Preventing Lung Disease In Preterm Babies
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Kangtai Drops Plan for China Vaccine JV With AstraZeneca
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Zimmer Biomet Pushes Two-Year US Sales Restructuring, May See Near Term Headwinds
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet Expects Paragon 28 To Power Double Digit Rise In 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
Korea Q4 Roundup: Major Firms’ Results Largely Favorable
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
US FDA’s Worldwide GMP Warnings Stack Up With Problems Found At Topical OTC Drug Firms
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
Estée Lauder Sues Walmart Alleging Sale of Counterfeit Beauty Products
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story
The Danish firm’s Yorvipath produced strong growth during its first full year on market, and Ascendis expects US approval this year for a weekly competitor to BioMarin’s Voxzogo in achondroplasia.
Scrip - February 12, 2026
The Danish firm’s Yorvipath produced strong growth during its first full year on market, and Ascendis expects US approval this year for a weekly competitor to BioMarin’s Voxzogo in achondroplasia.
Scrip - February 12, 2026
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share
The company’s positive topline Phase III results for the oral drug showed improvements in growth and body proportionality, including gains not seen with standard-of-care injections.
Scrip - February 12, 2026
The company’s positive topline Phase III results for the oral drug showed improvements in growth and body proportionality, including gains not seen with standard-of-care injections.
Scrip - February 12, 2026
Paul Hudson’s Legacy At Sanofi: Dupixent And Missed Opportunities
Dupixent grew from a €2bn drug to a €15bn behemoth during Hudson’s six years leading Sanofi, but a decision to end work on a GLP-1 agonist ahead of the metabolic/obesity boom could be a haunting misstep.
Scrip - February 12, 2026
Dupixent grew from a €2bn drug to a €15bn behemoth during Hudson’s six years leading Sanofi, but a decision to end work on a GLP-1 agonist ahead of the metabolic/obesity boom could be a haunting misstep.
Scrip - February 12, 2026
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals
After its ProfoundBio and Merus acquisitions in 2024 and 2025, Genmab could add Rina-S and petosemtamab to its two marketed cancer drugs, Epkinly and Tivdak, before its Darzalex royalty stream dries up.
Scrip - February 12, 2026
After its ProfoundBio and Merus acquisitions in 2024 and 2025, Genmab could add Rina-S and petosemtamab to its two marketed cancer drugs, Epkinly and Tivdak, before its Darzalex royalty stream dries up.
Scrip - February 12, 2026
Ipsen Eyes More Deals And Keen On Late-Stage Cancer Assets
CEO David Loew has been speaking about the French group’s external innovation strategy after posting another healthy set of financials.
Scrip - February 12, 2026
CEO David Loew has been speaking about the French group’s external innovation strategy after posting another healthy set of financials.
Scrip - February 12, 2026
Viking’s Oral Obesity Challenger Moves Fast Into Phase III
The San Diego-based biotech could be among the first rivals to Novo Nordisk and Eli Lilly with VK2735, and an oral version also now moving into a pivotal study.
Scrip - February 12, 2026
The San Diego-based biotech could be among the first rivals to Novo Nordisk and Eli Lilly with VK2735, and an oral version also now moving into a pivotal study.
Scrip - February 12, 2026
Europe Biotech Backers Link Up To Improve Sector’s Health
The European Life Sciences Coalition has been launched to boost investment in the sector.
Scrip - February 12, 2026
The European Life Sciences Coalition has been launched to boost investment in the sector.
Scrip - February 12, 2026
Sanofi Replaces CEO Paul Hudson With Merck KGaA’s Belén Garijo
Sanofi’s Paul Hudson will step down and be replaced by Belén Garijo, who will become the French group’s first ever female CEO.
Scrip - February 12, 2026
Sanofi’s Paul Hudson will step down and be replaced by Belén Garijo, who will become the French group’s first ever female CEO.
Scrip - February 12, 2026
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Kangtai Drops Plan for China Vaccine JV With AstraZeneca
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Korea Q4 Roundup: Major Firms’ Results Largely Favorable
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
Execs On The Move: February 2–6, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 12, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 12, 2026
FDA Holds ‘Refresher’ Town Hall On Low-Risk, General Wellness Medical Devices
The US FDA hosted a virtual town hall as a follow-up to final guidance the agency issued last month, which outlines its policy on general wellness medical devices that the agency considers low risk.
Medtech Insight - February 12, 2026
The US FDA hosted a virtual town hall as a follow-up to final guidance the agency issued last month, which outlines its policy on general wellness medical devices that the agency considers low risk.
Medtech Insight - February 12, 2026
Novocure’s Optune Pax First Home-Use Pancreatic Cancer Treatment Device Approved By FDA
Novocure’s Optune Pax is a wearable non-invasive device that uses electrical fields to disrupt the growth of cancer cells. A pivotal trial showed longer survival in patients who used the device than in those treated with chemotherapy alone.
Medtech Insight - February 12, 2026
Novocure’s Optune Pax is a wearable non-invasive device that uses electrical fields to disrupt the growth of cancer cells. A pivotal trial showed longer survival in patients who used the device than in those treated with chemotherapy alone.
Medtech Insight - February 12, 2026
Zimmer Biomet Pushes Two-Year US Sales Restructuring, May See Near Term Headwinds
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet Expects Paragon 28 To Power Double Digit Rise In 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
Wella Appoints CEO, LVMH Names Head of Beauty Group; Appointments Roundup
The Wella Company announces that former Sephora Americas CEO Calvin McDonald will take over as CEO of the hair care marketer April 2. Separately, LVMH names new head of its beauty group and Revlon appoints a chief operations officer.
HBW Insight - February 12, 2026
The Wella Company announces that former Sephora Americas CEO Calvin McDonald will take over as CEO of the hair care marketer April 2. Separately, LVMH names new head of its beauty group and Revlon appoints a chief operations officer.
HBW Insight - February 12, 2026
Zuellig Bolsters Consumer Health Offering In Asia with Bayer Deal
Singapore's Zuellig Pharma picks up consumer health brands with over 100 years of heritage through deal with Bayer.
HBW Insight - February 12, 2026
Singapore's Zuellig Pharma picks up consumer health brands with over 100 years of heritage through deal with Bayer.
HBW Insight - February 12, 2026
US FDA’s Worldwide GMP Warnings Stack Up With Problems Found At Topical OTC Drug Firms
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
Estée Lauder Sues Walmart Alleging Sale of Counterfeit Beauty Products
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Generics Bulletin - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Generics Bulletin - February 12, 2026
Samsung Bioepis Secures US Launch Date For Eylea Biosimilar – Though Later Than Others
Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.
Generics Bulletin - February 12, 2026
Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.
Generics Bulletin - February 12, 2026
Five Years To Go: Spotlight On Biosimilar Dupixent
With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.
Generics Bulletin - February 12, 2026
With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.
Generics Bulletin - February 12, 2026
Aspire Picks Up Irish Asset With Caragen Acquisition
UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.
Generics Bulletin - February 12, 2026
UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.
Generics Bulletin - February 12, 2026
Deals Of The Year 2025 Winners Revealed
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026
Podcast: Preventing Lung Disease In Preterm Babies
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026